

Supplementary Table 2. Univariable analysis between metabolic parameters and log-transformed IGI, DI, DI_o, and HOMA-B (*n*=470)

Per 1SD	Log(IGI)		Log(DI)		Log(DI _o)		Log(HOMA-B)	
	β	<i>P</i> value	β	<i>P</i> value	β	<i>P</i> value	β	<i>P</i> value
HbA1c	-0.386	<0.001	-0.458	<0.001	-0.387	<0.001	-0.468	<0.001
DM duration	-0.314	<0.001	-0.199	<0.001	-0.200	<0.001	-0.212	<0.001
Female sex	0.202	0.030	0.119	0.196	0.163	0.078	0.368	<0.001
HbA1c AUC	-0.224	<0.001	-0.135	0.002	-0.133	0.003	-0.156	<0.001
Age	-0.090	0.046	0.000	0.995	0.006	0.899	-0.056	0.199
BMI	0.262	<0.001	0.031	0.501	0.000	0.995	0.389	<0.001
HbA1c CV	0.059	0.240	0.028	0.575	0.013	0.801	0.118	0.007
SBP	0.005	0.897	-0.047	0.257	-0.042	0.320	0.011	0.794
DBP	0.041	0.311	-0.023	0.587	-0.031	0.454	0.034	0.403
Hypertension	0.154	0.084	0.100	0.261	0.047	0.601	0.304	<0.001
Dyslipidemia	0.152	0.080	0.086	0.335	0.100	0.264	0.200	0.021
Cardiovascular disease	0.134	0.384	0.176	0.247	0.190	0.213	0.200	0.192
HOMA-IR	0.200	<0.001	-	-	-	-	0.273	<0.001
ISI	-0.357	<0.001	-	-	-	-	-0.450	<0.001
DM medication duration								
Metformin	-0.227	<0.001	-0.165	<0.001	-0.158	<0.001	-0.137	0.001
Sulfonylurea	-0.236	<0.001	-0.171	<0.001	-0.165	<0.001	-0.155	<0.001
Glinide	-0.007	0.860	-0.009	0.814	-0.001	0.982	-0.039	0.326
GLP-1R agonist	0.036	0.374	-0.006	0.880	0.012	0.767	0.049	0.216
DPP-4 inhibitor	-0.177	<0.001	-0.142	<0.001	-0.126	0.002	-0.142	<0.001
TZD	-0.135	<0.001	-0.076	0.065	-0.065	0.113	-0.149	<0.001
SGLT2 inhibitor	-0.045	0.265	-0.026	0.523	-0.058	0.157	0.055	0.173
AGI	-0.127	0.001	-0.041	0.311	-0.040	0.323	-0.119	0.003
Insulin	-0.041	0.308	-0.024	0.558	-0.041	0.303	0.013	0.753

Standardized regression coefficients (β) and *P* values were obtained using a linear mixed model for repeated outcomes in the clustered data. IGI, insulinogenic index; DI, disposition index; DI_o, oral disposition index; HOMA-B, homeostasis model assessment of β -cell function; SD, standard deviation; HbA1c, glycosylated hemoglobin; DM, diabetes mellitus; HbA1c AUC, area under the curve of HbA1c over time; BMI, body mass index; HbA1c CV, coefficient of variation in HbA1c; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment for insulin resistance; ISI, Matsuda insulin sensitivity index; GLP-1R, glucagon-like peptide-1 receptor; DPP-4, dipeptidyl peptidase-4; TZD, thiazolidinedione; SGLT2, sodium-glucose cotransporter 2; AGI, alpha-glucosidase inhibitor.